mBio · 2019 · 79 citations · 32 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceDrug DiscoveryMedical MicrobiologyAntibacterial TherapyAntibiotic ResistanceBeta-lactam ResistanceCombination Antimicrobial TherapyMultidrug ResistanceAntibiotic CombinationsMacrolide AntibioticsMacrolide Resistance MechanismsMacrolide TherapyNovel Antibacterial Drug DiscoverySynergy With Beta-lactam CombinationsTime-kill Assaysβ-Lactam Antibiotics
The emergence of chronic MABC infections among immunocompromised populations and their inherent and acquired resistance to effective antibiotic therapy have created clinical challenges in advancing patients for transplant surgery and treating those with disease. There is an urgent need for new treatment regimens, and the repurposing of existing antibiotics provides a rapid strategy to advance a laboratory finding to patient care. Our recent discoveries that dual β-lactams, specifically the combination of ceftazidime with ceftaroline or ceftazidime with imipenem, have significant in vitro MIC values and kill curve activities and are effective against infected THP-1 human macrophages provide optimism for a dual β-lactam treatment strategy against MABC infections. The unexpected synergistic activities reported in this study create a new path of discovery to repurpose the large family of β-lactam drugs.
32
Versatile and open software for comparing large genomes
Stefan Kurtz, Adam M. Phillippy, Arthur L. Delcher et al. · Genome biology · 2004 · 5.8K citations · Full text
PHASTER: a better, faster version of the PHAST phage search tool
David Arndt, Jason R. Grant, Ana Marcu et al. · Nucleic Acids Research · 2016 · 3.8K citations · Full text